2 April 2025 - The approval is supported by the pivotal Phase 3 MycarinG study in gMG, which demonstrated that treatment with Rystiggo results in statistically significant improvements in generalised myasthenia gravis-specific outcomes, including MG-ADL which assesses everyday activities such as breathing, talking, swallowing, and being able to rise from a chair.

UCB Canada is pleased to announce that Rystiggo (rozanolixizumab injection) has received authorisation from Health Canada for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

Read UCB press release